Cutting edge: New chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity
Vincent Pavot1, Nicolas Rochereau2, Julien Rességuier3
1Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5305, Université de Lyon, Lyon F-69007, France; Groupe Immunité des Muqueuses et Agents Pathogènes, INSERM Centre d'Investigation Clinique en Vaccinologie 1408, Université de Lyon, Saint-Etienne F-42023, France; and.
Journal of Immunology (Baltimore, Md. : 1950)
|November 14, 2014
Summary
A novel chimeric ligand targeting Toll-like receptor 2 (TLR2) and NOD2 receptors synergistically enhances immune responses. This TLR/NOD molecule shows promise as a vaccine adjuvant for inducing robust systemic and mucosal immunity.
Area of Science:
- Immunology
- Vaccinology
- Innate Immunity
Background:
- Toll-like receptor (TLR) ligands are key innate immunity activators and potential vaccine adjuvants.
- The combined use of TLR and NOD-like receptor (NLR) agonists for immune enhancement is underexplored.
Purpose of the Study:
- To evaluate a novel chimeric ligand targeting both TLR2 and NOD2 receptors.
- To assess its efficacy in enhancing dendritic cell maturation and immune responses in vivo.
Main Methods:
- In vitro assessment of dendritic cell maturation markers and cytokine secretion.
- In vivo evaluation of systemic and mucosal immune responses in mice when coadministered with antigen-loaded nanoparticles.
Main Results:
- The chimeric NOD2/TLR2 ligand demonstrated synergistic enhancement of dendritic cell maturation markers, costimulatory molecules, and pro-inflammatory cytokine secretion.
- Co-administration with antigen nanoparticles induced high antigen-specific IgA and IgG titers at both systemic and mucosal sites.
Conclusions:
- Chimeric NOD/TLR ligands offer a promising strategy for vaccine adjuvant development.
- This approach can effectively induce both systemic and mucosal immunity, crucial for comprehensive vaccine efficacy.
